John Allan, MD

Articles

Expert Insights on BRUIN CLL-321: Pirtobrutinib in BTKi Pretreated CLL Patients

June 17th 2025

Panelists discuss how the positive BRUIN CLL-321 phase 3 trial results support pirtobrutinib use after covalent BTK inhibitor exposure and consider its role in second-line versus third-line treatment sequencing.

Clinical Approaches in Switching Between BTKi’s in R/R CLL & Practical Considerations for Drug Holidays

June 17th 2025

Panelists discuss how clinical trial data supports switching between different covalent BTK inhibitors for intolerance management, with 60-70% of patients experiencing resolution of the original toxicity.

Identifying BTKi Treatment Intolerance in R/R CLL

June 10th 2025

Panelists discuss how to define true BTK inhibitor intolerance versus manageable side effects and describe successful strategies for switching between covalent BTK inhibitors to maintain treatment efficacy.

Considerations with Retreatment of Venetoclax-Containing Regimens

June 10th 2025

Panelists discuss how retreatment with venetoclax may be appropriate in certain scenarios despite prior exposure, though continuous BTK inhibitor therapy is often preferred for patients with high-risk disease features.

Clinical Perspectives: 59yF with R/R CLL Experiencing BTKi Treatment-Related AE

June 3rd 2025

Panelists discuss how to manage BTK inhibitor-related adverse events including atrial fibrillation, bleeding, and gastrointestinal toxicities through dose modifications, supportive care, and potential drug switching strategies.

Expert Perspectives: Sequencing Strategies after Acalabrutinib + Venetoclax +/- Obinutuzumab as First-Line Therapy in CLL

June 3rd 2025

Panelists discuss how sequencing therapies becomes challenging when using combination regimens like acalabrutinib-venetoclax in frontline treatment, requiring careful consideration of retreatment strategies and resistance mutation testing.

Timing of Treatment Initiation in Relapsed CLL: Factoring in Prognostic and Patient Factors

May 27th 2025

Panelists discuss how they approach prognostic marker testing at relapse, the importance of ruling out Richter's transformation, and timing of treatment initiation based on disease characteristics and progression patterns.

Clinical Perspectives: 59yF with R/R CLL after Time-Limited Therapy

May 27th 2025

Panelists discuss how a CLL patient with initially low-risk disease and mutated IGHV unexpectedly relapsed early after venetoclax-obinutuzumab treatment with acquisition of high-risk features, presenting unique management challenges.

Unmet Needs and Future Directions in Care in CLL

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

February 15th 2023

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

February 1st 2023

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.